Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Race Oncology Ltd
RACCurrent price
1.36 AUD
-0.015 AUD (-1.09%)
Last closed
1.38 AUD
Company
www.raceoncology.com
ISIN
AU000000RAC3
Sector
Healthcare
Industry
Biotechnology
Exchange
Australian Securities Exchange
Capitalization
246 421 963 AUD
Yield for 12 month
+61.90 %
1Y
3Y
5Y
10Y
15Y
RAC
Race Oncology Limited, a clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments. The company's lead product is bisantrene, a small molecule chemotherapeutic that has a clinical history with demonstrated therapeutic benefits in adult and paediatric patients. It is advancing reformulated bisantrene (RC220) to address the unmet need of patients across various oncology indications with a clinical focus on anthracycline combination to deliver cardioprotection and enhanced anticancer activity in solid tumors. The company is also exploring RC220 as a low intensity treatment for acute myeloid leukaemia. In addition, it is investigating the effect of bisantrene on the m6A RNA pathway, following independent research identifying bisantrene as the potent inhibitor of fat mass and obesity-associated protein. The company has collaborations with Astex, City of Hope, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong, and University of Newcastle. The company was formerly known as Coronado Resources Limited. Race Oncology Limited was incorporated in 2011 and is headquartered in Sydney, Australia. Address: Gateway, 1 Macquarie Place, Sydney, NSW, Australia, 2000
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
10.25 AUDP/E ratio
–Dividend Yield
–Current Year
+4 085 723 AUD
Last Year
+3 198 778 AUD
Current Quarter
–
Last Quarter
+4 085 723 AUD
Current Year
+1 418 472 AUD
Last Year
+2 911 804 AUD
Current Quarter
-785 233 AUD
Last Quarter
+3 942 236 AUD
Key Figures RAC
1 year
3 years
5 years
10 years
EBITDA
-14 495 190 AUD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-38.63 %
PEG Ratio
–
Return On Equity TTM
-63.10 %
Wall Street Target Price
10.25 AUD
Revenue TTM
4 085 723 AUD
Book Value
0.11 AUD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-100.00 %
Dividend Yield
–
Gross Profit TTM
1 130 669 AUD
Earnings per share
-0.082 AUD
Diluted Eps TTM
-0.082 AUD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics RAC
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History RAC
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation RAC
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
60.3129
Enterprise Value EBITDA
-21.5133
Price Book MRQ
13.3755
Financials RAC
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators RAC
For 52 weeks
0.65 AUD
2.13 AUD
50 Day MA
1.49 AUD
Shares Short Prior Month
–
200 Day MA
1.59 AUD
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart